Stoke Therapeutics Appoints Biotech Veteran Arthur Tzianabos, Ph.D. to Board of Directors
September 17, 2018 08:00 AM Eastern Daylight Time
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., today announced that veteran biotech executive Arthur Tzianabos, Ph.D., who has extensive experience in the development and commercialization of rare disease treatments, will join the company’s board of directors.
“Stoke’s oligonucleotide therapeutics have the potential to be true breakthroughs for patients with epilepsy and other rare genetic disorders”
Dr. Tzianabos, the CEO and president of Homology Medicines, joins the board as Stoke is advancing toward the clinic with a pipeline of oligonucleotide therapies that aim to address the root cause of severe genetic diseases, starting with Dravet Syndrome.
“Arthur brings terrific experience in rare disease and genetic medicine – and he has a proven track record of bringing novel therapies from research stage through to market,” said Ed Kaye, M.D., Stoke’s president and CEO. “We look forward to his playing an active role on our board as we push ahead with new methods to increase gene expression to treat a wide array of genetic diseases.”
“Stoke’s oligonucleotide therapeutics have the potential to be true breakthroughs for patients with epilepsy and other rare genetic disorders,” Dr. Tzianabos said. “I’m delighted to have the opportunity to work with Dr. Kaye and the Stoke team at this exciting moment in the company’s growth.”
At Homology, Dr. Tzianabos leads efforts to develop genetic medicines by leveraging its in vivo gene therapy and nuclease-free gene editing platform for patients with rare genetic diseases. He previously served as president and CSO of OvaScience, where he translated early science into treatments for fertility patients. Dr. Tzianabos also spent nine years at Shire, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders and worked closely with the business development team to build Shire’s product pipeline through investments and acquisitions. Earlier in his career, Dr. Tzianabos was a principal investigator and faculty member at Harvard Medical School for 15 years, reaching the rank of associate professor of medicine and maintaining laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters and patents. He is a member of the board of directors for gene therapy company Akouos and serves on the development board for the University of New Hampshire’s College of Life Sciences and Agriculture. Dr. Tzianabos holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.
About Stoke Therapeutics
Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye and liver. Stoke was launched in 2018 with a $40 million Series A investment funded by Apple Tree Partners. For more information visit www.stoketherapeutics.com and follow Stoke on Twitter @StokeTx.
Ten Bridge Communications Stephanie Simon, 617-581-9333 firstname.lastname@example.org